Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, has announced its participation in three major investor conferences in September 2025.
CEO Warner Biddle will participate in fireside chat presentations at the 2025 Wells Fargo Healthcare Conference (September 3rd, 11:00 a.m. ET), the Morgan Stanley 23rd Annual Global Healthcare Conference (September 8th, 4:05 p.m. ET), and the H.C. Wainwright 27th Annual Global Investment Conference (September 9th, 11:00 a.m. ET).
Investors can access live webcasts through Kyverna's investor relations website, with replays available for 90 days post-events.
Positive
- None.
Negative
- None.
News Market Reaction – KYTX
In the Aug 26 session, KYTX declined 0.79%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences:
2025 Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 3rd, 2025
Time: 11:00 a.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Fireside Chat
Date: Monday, September 8th, 2025
Time: 4:05 p.m. ET
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat
Date: Tuesday, September 9th, 2025
Time: 11:00 a.m. ET
Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. Archived replays of all events will be available on the website for approximately 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
